Viva Biotech Holdings (HKSE:01873) EV-to-EBIT : 17.46 (As of Jun. 06, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Viva Biotech Holdings's Enterprise Value is HK$2,303 Mil. Viva Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$132 Mil. Therefore, Viva Biotech Holdings's EV-to-EBIT for today is 17.46.

The historical rank and industry rank for Viva Biotech Holdings's EV-to-EBIT or its related term are showing as below:

HKSE:01873' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.03 Med: 10.61 Max: 61.84
Current: 17.46

During the past 8 years, the highest EV-to-EBIT of Viva Biotech Holdings was 61.84. The lowest was -52.03. And the median was 10.61.

HKSE:01873's EV-to-EBIT is ranked worse than
63.68% of 424 companies
in the Biotechnology industry
Industry Median: 9.96 vs HKSE:01873: 17.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Viva Biotech Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$3,197 Mil. Viva Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$132 Mil. Viva Biotech Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.13%.

Viva Biotech Holdings EV-to-EBIT Historical Data

The historical data trend for Viva Biotech Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings EV-to-EBIT Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

19.48

-52.31

17.37

-18.75

24.23

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial									17.37	-	-18.75	-	24.23

Competitive Comparison of Viva Biotech Holdings's EV-to-EBIT

For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's EV-to-EBIT falls into.

Viva Biotech Holdings EV-to-EBIT Calculation

Viva Biotech Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2303.406	/	131.942
	=	17.46

Viva Biotech Holdings's current Enterprise Value is HK$2,303 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$132 Mil.

Viva Biotech Holdings (HKSE:01873) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Viva Biotech Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	131.942	/	3197.0505
	=	4.13 %

Viva Biotech Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was HK$3,197 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$132 Mil.

Viva Biotech Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings (HKSE:01873) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines